<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="pmc">brjcancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">2539180</article-id><article-id pub-id-type="pmc">2247066</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Selby</surname><given-names>P. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Powles</surname><given-names>R. L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Easton</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Perren</surname><given-names>T. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stolle</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jameson</surname><given-names>B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fiddian</surname><given-names>A. P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tryhorn</surname><given-names>Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Stern</surname><given-names>H.</given-names></name></contrib></contrib-group><aff>Institute of Cancer Research, Royal Marsden Hospital, Surrey, UK.</aff><pub-date pub-type="ppub"><month>3</month><year>1989</year></pub-date><volume>59</volume><issue>3</issue><fpage>434</fpage><lpage>438</lpage><abstract><p>Eighty-two patients were randomly allocated to receive intravenous acyclovir 5 mg kg-1 t.d.s. for 23 days followed by oral acyclovir 800 mg 6-hourly for 6 months or matching placebos after allogeneic bone marrow transplantation. Herpes simplex and varicella zoster virus infections were significantly reduced during the period of administration of acyclovir. No reduction in cytomegalovirus infection was demonstrated. The drug was not toxic.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00125-0114.tif" xlink:title="scanned-page" xlink:role="434" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00125-0115.tif" xlink:title="scanned-page" xlink:role="435" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00125-0116.tif" xlink:title="scanned-page" xlink:role="436" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00125-0117.tif" xlink:title="scanned-page" xlink:role="437" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00125-0118.tif" xlink:title="scanned-page" xlink:role="438" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

